On November 9, 2021 MaaT Pharma (EURONEXT: MAAT – the "Company"), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, reported that additional results from its Phase 2 trial HERACLES (NCT03359980) and extended results from its compassionate use (EAP) program for lead microbiome therapeutic MaaT013 will be discussed in an oral presentation at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting held from December 11-14, 2021 (Press release, MaaT Pharma, NOV 9, 2021, View Source [SID1234594887]). With these additional data from its MaaT013 Phase 2 trial and from MaaT013 early access program, this is the second year that results from the Company are selected for an oral presentation, and the fifth year in a row that the Company presents data at the ASH (Free ASH Whitepaper) conference.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The HERACLES results include data from 24 patients with grade III-IV, steroid-resistant, gastrointestinal (GI)-predominant, acute Graft-versus-Host-Disease (aGvHD) that were treated with MaaT013 as second line therapy. The EAP results include data from 52 patients treated with MaaT013, with steroid-resistant or steroid-dependent aGvHD with GI involvement, who had previously failed 1 to 6 lines (median: 3) lines of systemic therapy; MaaT Pharma provided the product to hospitals under a compassionate access program in France ("accès compassionnel"- EAP). MaaT013 is a high-richness, high-diversity Microbiome Ecosystem Therapy (MET) derived from pooled donations from strictly vetted healthy individuals and is presented as an enema.
The data will be presented by Prof. Mohamad Mohty, professor and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University.
Oral Presentation details:
Title: Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program
Abstract No: 262
Session Name: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Treatment of acute and chronic graft vs. host disease
Date/Time: Saturday, December 11, 2021; 2:45 PM EST
Room: Georgia World Congress Center, B304-B305
MaaT Pharma will announce the results through a press release on Monday, December 13, 2021.